{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:33:06Z","timestamp":1793295186794,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Treating patients for tuberculosis (TB) infection prevents future cases and transmission. Long treatment regimens have been associated with low completion rates. We describe a 1-decade experience with treating children and adolescents for TB infection (TBI) with 3 months of once-weekly doses of isoniazid and rifapentine (3HP).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This was a retrospective review (2014\u20132024) of 2 to &lt;21 year olds who received 3HP under directly observed therapy for TBI. We abstracted demographic data, testing methods and treatment course information. Our primary outcome was treatment completion; our secondary outcome was adverse events (AEs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eight hundred two patients met inclusion criteria; 94.1% completed therapy. Completion rates were not associated with demographic data or testing methods. The most common reasons for not completing 3HP were AEs (23\/802, 3%), moving out of the area (11, 1.4%) and pill burden (7, 0.9%). AEs resulting in failure to complete 3HP were rare. These included vomiting (15; 2 with elevated aspartate aminotransferase\/alanine aminotransferase), abdominal pain (7, all with normal aspartate aminotransferase\/alanine aminotransferase), rash (6), angioedema (4) and myalgias (2); 16\/23 had &gt;1 AE. Of the 23 with AEs, 20 began alternative regimens [rifampin (12), levofloxacin (5) and isoniazid (3)], and 17\/20 (85%) completed TBI therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Over 94% of children as young as 2 years of age completed 3HP for TBI, which is remarkable considering the large pill burden and lack of child-friendly formulations available in the United States. The only factor associated with treatment completion was the presence of an AE.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004767","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T18:00:12Z","timestamp":1739815212000},"page":"755-758","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Completion, Safety and Tolerability of Once-weekly Isoniazid and Rifapentine for Tuberculosis Infection by Children and Adolescents"],"prefix":"10.1097","volume":"44","author":[{"given":"Andrea T.","family":"Cruz","sequence":"first","affiliation":[{"name":"Divisions of Infectious Diseases"},{"name":"Emergency Medicine, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay H.","family":"Cameron","sequence":"additional","affiliation":[{"name":"Texas Children\u2019s Pediatrics, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Starke","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"R1-20250723","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent tuberculosis infection acceptance and completion in the United States and Canada.","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"421","DOI":"10.5588\/ijtld.13.0688","article-title":"Risk factors for treatment default in close contacts with latent tuberculosis infection.","volume":"18","author":"Fiske","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"R3-20250723","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/INF.0b013e318236984f","article-title":"Increasing adherence for latent tuberculosis infection therapy with health department-administered therapy.","volume":"31","author":"Cruz","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R4-20250723","doi-asserted-by":"crossref","first-page":"e0298628","DOI":"10.1371\/journal.pone.0298628","article-title":"Interpreter usage and associations with latent tuberculosis infection treatment acceptance and completion in the USA among non-US-born persons, 2012-2017.","volume":"19","author":"Gonzalez-Reyes","year":"2024","journal-title":"PLoS One"},{"key":"R5-20250723","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5588\/ijtld.14.0373","article-title":"Latent tuberculosis infection in the United States and Canada: who completes therapy and why?","volume":"19","author":"Hirsch-Moverman","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"R6-20250723","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults.","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.5588\/ijtld.14.0286","article-title":"Safety and completion of a 4-month course of rifampicin for latent tuberculosis infection in children.","volume":"18","author":"Cruz","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"R8-20250723","doi-asserted-by":"crossref","first-page":"e20172838","DOI":"10.1542\/peds.2017-2838","article-title":"Completion rate and safety of tuberculosis infection treatment with shorter regimens.","volume":"141","author":"Cruz","year":"2018","journal-title":"Pediatrics"},{"key":"R9-20250723","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/INF.0000000000001164","article-title":"Safety and adherence for 12 weekly doses of isoniazid and rifapentine for pediatric tuberculosis.","volume":"35","author":"Cruz","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20250723","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020.","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"R11-20250723","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection.","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"R12-20250723","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"key":"R13-20250723","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12879-017-2245-8","article-title":"Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin, and 3 months of isoniazid and rifapentine.","volume":"17","author":"McClintock","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R14-20250723","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(23)00096-6","article-title":"Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.","volume":"11","author":"Winters","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R15-20250723","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies."},{"key":"R16-20250723","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial.","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"R17-20250723","doi-asserted-by":"crossref","first-page":"e2021054663","DOI":"10.1542\/peds.2021-054663","article-title":"Tuberculosis infection in children and adolescents: testing and treatment.","volume":"148","author":"Nolt","year":"2021","journal-title":"Pediatrics"},{"key":"R18-20250723","doi-asserted-by":"crossref","first-page":"e0246291","DOI":"10.1371\/journal.pone.0246291","article-title":"Hypersensitivity reactions to multiple anti-tuberculosis drugs.","volume":"16","author":"Shin","year":"2021","journal-title":"PLoS One"},{"key":"R21-20250723","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2352-4642(21)00052-3","article-title":"Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study.","volume":"5","author":"Malik","year":"2021","journal-title":"Lancet Child Adolesc Health"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T20:00:21Z","timestamp":1753300821000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004767","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}